High-dose interleukin-2 (HD IL-2) for metastatic renal Cell carcinoma (mRCC): Contemporary utilization trends in the United States Allard, C. B., Gelpi-Hammerschmidt, F., Harshman, L., Faiena, I., Modi, P. K., Chung, B. I., Singer, E. A., Chang, S. L. AMER SOC CLINICAL ONCOLOGY. 2015

View details for DOI 10.1200/jco.2015.33.7_suppl.449

View details for Web of Science ID 000356886700446